• Text in Japanese

Publish  Cancer Research

Researchers from Osaka University, National Center of Neurology and Psychiatry, and Niigata University identify the amino acid arginine as a potential disease-modifying drug for polyglutamine diseases, such as familial spinocerebellar ataxia and Huntington disease

Fig. 1　Conformational change of polyglutamine proteins in the polyglutamine diseases and the effect of arginine as a protein conformation stabilizer


Click to enlarge

Familial spinocerebellar ataxia (SCA), Huntington disease, and spinal and bulbar muscular atrophy are inherited neurodegenerative diseases. Because of their similar molecular pathogenesis, they are also called polyglutamine (polyQ) diseases. Current treatments for these diseases only focus on symptomatic improvement, as disease-modifying approaches have remained an unmet clinical need. Now, researchers from Osaka University, National Center of Neurology and Psychiatry, and Niigata University have identified the natural amino acid arginine as a novel potential approach to attenuate symptoms, as well as the molecular pathogenesis of polyQ diseases. In a new study published in Brain, they show how arginine improved neurological symptoms when given to mice with polyQ diseases before and even after the onset of symptoms.

PolyQ diseases are caused by an abnormal expansion of a specific DNA sequence consisting of the three bases: cytosine, adenine and guanine (CAG). In certain genes that are important for normal neuronal function, CAG can appear back to back multiple times. The number of CAG repetitions varies between individuals and different neuronal genes, but if the repetition happens too often, the function of the protein that is built from the gene can be severely impaired. While an increased number of CAG repeats results in protein misfolding and aggregation with concurrent damage to nerve cells, medication that actually halts this process of neurodegeneration has yet to be developed.

“We cannot cure patients with polyglutamine diseases. Instead, we have had to resort to symptomatic therapy as the only medical option,” says corresponding author of the study Yoshitaka Nagai. “The goal of our study was to find a new disease-modifying drug for polyglutamine diseases.”

To achieve their goal, the researchers turned to chemical chaperones, molecules that facilitate proper protein folding, to prevent the build-up of protein aggregates. By screening a number of chemical chaperones for their ability to prevent protein aggregation in a test tube, they discovered that arginine, a naturally occurring amino acid, had the strongest inhibiting effect on protein aggregation. In a separate set of experiments using living cells, the researchers then found that arginine was also able to prevent aggregate formation of polyQ proteins.

“These findings show how arginine could alleviate the detrimental effects of polyQ aggregate formation,” says lead author of the study Eiko Minakawa. “We next wanted to know if arginine could slow down or halt the progression of different polyQ diseases in living organisms.”

To test the therapeutic potential of arginine, the researchers utilized well-established mouse models of familial spinocerebellar ataxia, and spinal and bulbar muscular atrophy. When added to their drinking water before symptom onset, arginine inhibited polyQ protein aggregation as well as suppressed motor impairment and neurodegeneration of the mice. Intriguingly, even after the onset of neurological symptoms, arginine was able to ameliorate the detrimental effects of familial spinocerebellar ataxia.

“These are striking results that show how arginine has therapeutic potential for familial spinocerebellar ataxia, which to date has been an incurable disease,” says Nagai. “Our next goal is to conduct clinical trials to use arginine as a novel therapy for polyglutamine diseases including spinocerebellar ataxias.”

###

The article, “Arginine is a disease modifier for polyglutamine disease models that stabilizes the polyglutamine protein conformation,” is published in Brain at DOI:10.1093/brain/awaa115

Summary: Researchers from Osaka University, National Center of Neurology and Psychiatry, and Niigata University identified the amino acid arginine as a potential disease-modifying drug for polyglutamine diseases, including familial spinocerebellar ataxia and Huntington disease. Using various mice models of polyglutamine diseases, they showed that arginine prevents polyglutamine protein aggregation, improves motor function and suppresses neurodegeneration of mice. The results of this study could facilitate the clinical use of arginine for polyglutamine diseases that are, to date, incurable.

Primary keyword:  Medicine

Additional keywords: Biochemistry, Cell Biology, Genetics, Molecular Biology

Fig. 2 Arginine suppresses the compound eye degeneration of SCA3 model fly (MJDtr-Q78(S)).
Expression of an expanded polyglutamine protein leads to neuronal degeneration in the compound eye of SCA3 model fly (upper right) compared with the wild-type control fly (upper left). Arginine administration suppresses this compound eye degeneration (bottom)

Click to enlarge

Fig. 3 Arginine suppresses the neuronal degeneration in the cerebellum of SCA1 model mice. SCA1 model mice develop the degeneration of Purkinje cells, one of the neuronal cell populations in the cerebellum (left, asterisks show regions with Purkinje cell degeneration). Arginine administration alleviates Purkinje cell degeneration (right).

Click to enlarge

Title: “Arginine is a disease modifier for polyglutamine disease models that stabilizes the polyglutamine protein conformation”

Journal: Brain

Authors: Eiko N. Minakawa, Helena Akiko Popiel, Masayoshi Tada, Toshiaki Takahashi, Hiroshi Yamane, Yuji Saitoh, Yasuo Takahashi, Daisaku Ozawa, Akiko Takeda, Toshihide Takeuchi, Yuma Okamoto, Kazuhiro Yamamoto, Mari Suzuki, Hiromi Fujita, Chiyomi Ito, Hiroko Yagihara, Yuko Saito, Kei Watase, Hiroaki Adachi, Masahisa Katsuno, Hideki Mochizuki, Kentaro Shiraki, Gen Sobue, Tatsushi Toda, Keiji Wada, Osamu Onodera, Yoshitaka Nagai

DOI:10.1093/brain/awaa115

Funded by: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development, Japan Science and Technology Agency